Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June. It ...

Most of the top 20 are American. The first European company is in 25th place – Denmark’s Novo Nordisk, famed for its ...

Earlier in November, Novo Nordisk's Wegovy weight-loss drug sales beat its forecast, in an obesity drug market that some ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...

Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money.

Novo Nordisk’s blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles ...

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Boxes of the injectable weight-loss drug Wegovy are seen in a pharmacy in Chicago on April ... The efforts by Eli Lilly and ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

On October 22, Novo Nordisk (Novo) nominated semaglutide products, which include its popular drugs marketed as Ozempic for type 2 diabetes and ...